BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21571862)

  • 1. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
    Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; Hennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H
    Cancer Res; 2011 Jul; 71(13):4412-22. PubMed ID: 21571862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling.
    Kaowinn S; Jun SW; Kim CS; Shin DM; Hwang YH; Kim K; Shin B; Kaewpiboon C; Jeong HH; Koh SS; Krämer OH; Johnston RN; Chung YH
    Cell Oncol (Dordr); 2017 Dec; 40(6):549-561. PubMed ID: 28776259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.
    Stukova M; Hall MD; Tsotsoros SD; Madigan JP; Farrell NP; Gottesman MM
    J Inorg Biochem; 2015 Aug; 149():45-8. PubMed ID: 26021697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.
    Kaewpiboon C; Srisuttee R; Malilas W; Moon J; Oh S; Jeong HG; Johnston RN; Assavalapsakul W; Chung YH
    Mol Med Rep; 2015 Mar; 11(3):2315-21. PubMed ID: 25395162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
    Zhang X; Qi Z; Yin H; Yang G
    Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.
    Stronach EA; Cunnea P; Turner C; Guney T; Aiyappa R; Jeyapalan S; de Sousa CH; Browne A; Magdy N; Studd JB; Sriraksa R; Gabra H; El-Bahrawy M
    Oncotarget; 2015 Oct; 6(31):31593-603. PubMed ID: 26267317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells.
    Yu SL; Lee DC; Son JW; Park CG; Lee HY; Kang J
    Oncol Rep; 2013 Sep; 30(3):1293-300. PubMed ID: 23817620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
    Cooke SL; Ng CK; Melnyk N; Garcia MJ; Hardcastle T; Temple J; Langdon S; Huntsman D; Brenton JD
    Oncogene; 2010 Sep; 29(35):4905-13. PubMed ID: 20581869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.
    Stronach EA; Chen M; Maginn EN; Agarwal R; Mills GB; Wasan H; Gabra H
    Neoplasia; 2011 Nov; 13(11):1069-80. PubMed ID: 22131882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT1‑HDAC4 signaling induces epithelial‑mesenchymal transition and sphere formation of cancer cells overexpressing the oncogene, CUG2.
    Kaowinn S; Kaewpiboon C; Koh SS; Krämer OH; Chung YH
    Oncol Rep; 2018 Nov; 40(5):2619-2627. PubMed ID: 30226605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
    BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
    Sakai W; Swisher EM; Jacquemont C; Chandramohan KV; Couch FJ; Langdon SP; Wurz K; Higgins J; Villegas E; Taniguchi T
    Cancer Res; 2009 Aug; 69(16):6381-6. PubMed ID: 19654294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of STAT1-Driven Transcriptional Activity by Histone Deacetylases.
    Owusu BY; Klampfer L
    Methods Mol Biol; 2017; 1510():277-285. PubMed ID: 27761828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
    Moon J; Kaowinn S; Cho IR; Min DS; Myung H; Oh S; Kaewpiboon C; Kraemer OH; Chung YH
    Biochem Biophys Res Commun; 2016 Jun; 474(3):428-434. PubMed ID: 27150631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recently identified drug resistance biomarkers in ovarian cancer.
    Davidson B
    Expert Rev Mol Diagn; 2016; 16(5):569-78. PubMed ID: 26895188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
    Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza A virus-induced host caspase and viral PA-X antagonize the antiviral host factor, histone deacetylase 4.
    Galvin HD; Husain M
    J Biol Chem; 2019 Dec; 294(52):20207-20221. PubMed ID: 31757810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.